
    
      This will be an open-label pilot study in which IgAN patients with persistent proteinuria
      despite maximum dose of ARB treatment will be assigned to receive Aliskiren. There is the
      optional addition of other anti-hypertensive agents to achieve an optimal target blood
      pressure of <130/80 mmHg.
    
  